EA202191379A1 - Комбинированное лечение nafld и nash - Google Patents

Комбинированное лечение nafld и nash

Info

Publication number
EA202191379A1
EA202191379A1 EA202191379A EA202191379A EA202191379A1 EA 202191379 A1 EA202191379 A1 EA 202191379A1 EA 202191379 A EA202191379 A EA 202191379A EA 202191379 A EA202191379 A EA 202191379A EA 202191379 A1 EA202191379 A1 EA 202191379A1
Authority
EA
Eurasian Patent Office
Prior art keywords
nafld
combined
nash treatment
nash
treatment
Prior art date
Application number
EA202191379A
Other languages
English (en)
Inventor
Юнь-Цзюн Чой
Чарльз А. Макуэртер
Original Assignee
Саймабэй Терапьютикс, Инк.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Саймабэй Терапьютикс, Инк. filed Critical Саймабэй Терапьютикс, Инк.
Publication of EA202191379A1 publication Critical patent/EA202191379A1/ru

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/192—Carboxylic acids, e.g. valproic acid having aromatic groups, e.g. sulindac, 2-aryl-propionic acids, ethacrynic acid 
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/22—Hormones
    • A61K38/26—Glucagons
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2121/00—Preparations for use in therapy
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Epidemiology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Endocrinology (AREA)
  • Immunology (AREA)
  • Zoology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nutrition Science (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Physiology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)

Abstract

Комбинированное лечение NAFLD, включая NASH, селаделпаром или его солью и агонистом рецептора глюкагон-подобного пептида-1 (GLP-1).
EA202191379A 2018-11-16 2019-11-13 Комбинированное лечение nafld и nash EA202191379A1 (ru)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201862768226P 2018-11-16 2018-11-16
PCT/US2019/061159 WO2020102337A1 (en) 2018-11-16 2019-11-13 Combination treatment of nafld and nash

Publications (1)

Publication Number Publication Date
EA202191379A1 true EA202191379A1 (ru) 2021-08-06

Family

ID=68835315

Family Applications (1)

Application Number Title Priority Date Filing Date
EA202191379A EA202191379A1 (ru) 2018-11-16 2019-11-13 Комбинированное лечение nafld и nash

Country Status (14)

Country Link
US (1) US20200155650A1 (ru)
EP (1) EP3880185A1 (ru)
JP (1) JP2022507644A (ru)
KR (1) KR20210092754A (ru)
CN (1) CN113301889A (ru)
AU (1) AU2019378845A1 (ru)
BR (1) BR112021009038A2 (ru)
CA (1) CA3118961A1 (ru)
EA (1) EA202191379A1 (ru)
IL (1) IL283200A (ru)
MX (1) MX2021005724A (ru)
SG (1) SG11202104951RA (ru)
WO (1) WO2020102337A1 (ru)
ZA (1) ZA202103188B (ru)

Families Citing this family (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP3119384B1 (en) 2014-03-20 2018-09-12 CymaBay Therapeutics, Inc. Treatment of intrahepatic cholestatic diseases
US10272058B2 (en) 2014-03-20 2019-04-30 Cymabay Therapeutics, Inc. Treatment of intrahepatic cholestatic diseases
US10512622B2 (en) 2017-07-14 2019-12-24 Cymabay Therapeutics, Inc. Treatment of intrahepatic cholestatic diseases
US11478533B2 (en) * 2020-04-27 2022-10-25 Novo Nordisk A/S Semaglutide for use in medicine
KR20240118914A (ko) 2021-01-20 2024-08-05 바이킹 테라퓨틱스 인코포레이티드 대사 및 간 질환 치료를 위한 조성물 및 방법
US20240216476A1 (en) * 2021-04-27 2024-07-04 Aardvark Therapeutics, Inc. Combination of bitter receptor agonist and gut-signaling compound
WO2024059480A2 (en) * 2022-09-12 2024-03-21 Eli Lilly And Company A gip/glp1 for use in therapy

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
PT1667964E (pt) 2003-09-19 2009-09-02 Janssen Pharmaceutica Nv Ácidos 4-((fenoxialquil)tio)-fenoxiacéticos e análogos
JO3006B1 (ar) 2005-09-14 2016-09-05 Janssen Pharmaceutica Nv املاح ليسين مبتكرة من مشتقات حامض 4-((فينوكسي الكيل)ثيو) فينوكسي الخليك
US10272058B2 (en) * 2014-03-20 2019-04-30 Cymabay Therapeutics, Inc. Treatment of intrahepatic cholestatic diseases
MX369921B (es) 2014-04-11 2019-11-26 Cymabay Therapeutics Inc Tratamiento de la hgna y ehna.
CN110545836A (zh) * 2017-01-24 2019-12-06 马克雷根有限公司 用载脂蛋白模拟物治疗与年龄有关的黄斑变性和其他眼部疾病

Also Published As

Publication number Publication date
ZA202103188B (en) 2022-10-26
EP3880185A1 (en) 2021-09-22
JP2022507644A (ja) 2022-01-18
MX2021005724A (es) 2021-07-21
AU2019378845A1 (en) 2021-06-03
SG11202104951RA (en) 2021-06-29
US20200155650A1 (en) 2020-05-21
KR20210092754A (ko) 2021-07-26
IL283200A (en) 2021-06-30
BR112021009038A2 (pt) 2021-08-10
WO2020102337A1 (en) 2020-05-22
CA3118961A1 (en) 2020-05-22
CN113301889A (zh) 2021-08-24
AU2019378845A8 (en) 2021-06-17

Similar Documents

Publication Publication Date Title
EA202191379A1 (ru) Комбинированное лечение nafld и nash
DK3989972T3 (da) Glucagon-lignende peptid-1-receptor-agonister
DK3806855T5 (da) GLP-1-receptoragonister og anvendelser deraf
DK3806955T3 (da) GLP-1-receptoragonister og anvendelser deraf
EA202090392A3 (ru) Соединения-коагонисты гип и гпп-1
MX2021005725A (es) Tratamiento de la obesidad y sus complicaciones.
ECSP19046893A (es) Nuevos compuestos como agonistas peptídicos trigonales de los receptores de glp1/glucagón/gip
CO2018007582A2 (es) Método para tratar o mejorar trastornos metabólicos con proteínas de unión para el receptor peptídico inhibidor gástrico (gipr) en combinación con agonistas de glp-1
MX2019006427A (es) Nuevos compuestos como agonistas peptidicos de receptores de glp1/glucagon/gip.
PE20200013A1 (es) Metodo para tratar o mejorar trastornos metabolicos con proteinas de union para el receptor peptidico inhibidor gastrico (gipr) en combinacion con agonistas de glp-1
MX2015009433A (es) Polipeptidos novedosos que tienen actividad liberadora de hormonas de la saciedad.
EA201992475A1 (ru) КОМБИНАЦИЯ, СОДЕРЖАЩАЯ ТАКОЙ АГОНИСТ PPAR, КАК ЭЛАФИБРАНОР, И ИНГИБИТОР АЦЕТИЛ-КоА-КАРБОКСИЛАЗЫ (АКК)